Use of Maribavir for Multidrug Resistant Cytomegaloviremia in a Pediatric Oncology Patient

James E. Fisher, Kevin Mulieri, Elizabeth Finch, Jessica E. Ericson

Research output: Contribution to journalArticlepeer-review

Abstract

Resistant and refractory cytomegalovirus (CMV) viremia can limit the provision of chemotherapy due to myelosuppression and end-organ dysfunction. Few therapies are available for children with clinically significant CMV viremia. We successfully used maribavir for a 4-year-old patient with lymphoma to complete his chemotherapy course. Resistance to maribavir did result after many months of therapy.

Original languageEnglish (US)
Pages (from-to)E244-E247
JournalJournal of pediatric hematology/oncology
Volume46
Issue number3
DOIs
StatePublished - Apr 1 2024

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this